Andreas SchÃ¤fer

List of Publications by Year
in descending order

89	3,119	185998 28	168136 53
papers	citations	h-index	g-index

93	93	93	3870
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Therapeutic Hypothermia Following Cardiac Arrest After the TTM2 trial â€“ More Questions Raised Than Answered. Current Problems in Cardiology, 2023, 48, 101046.	1.1	10
2	Anticoagulants for stroke prevention in heart failure with reduced ejection fraction. Clinical Research in Cardiology, 2022, 111, 1-13.	1.5	10
3	Fulminant parvovirus B19 myocarditis after chemotherapy: full recovery after antiviral therapy with tenofovir. Clinical Research in Cardiology, 2022, 111, 233-236.	1.5	5
4	Impella Mechanical Circulatory Support for Takotsubo Syndrome With Shock: A Retrospective Multicenter Analysis. Cardiovascular Revascularization Medicine, 2022, 40, 113-119.	0.3	9
5	Clopidogrel or ticagrelor in elderly patients with acute coronary syndromes â€“ Nihil nocere!. International Journal of Cardiology, 2022, , .	0.8	0
6	Intracranial haemorrhage in adult patients on venoarterial extracorporeal membrane oxygenation. European Heart Journal: Acute Cardiovascular Care, 2022, 11, 303-311.	0.4	4
7	Computed-Tomography as First-line Diagnostic Procedure in Patients With Out-of-Hospital Cardiac Arrest. Frontiers in Cardiovascular Medicine, 2022, 9, 799446.	1.1	11
8	Intracoronary Application of Super-Saturated Oxygen to Reduce Infarct Size Following Myocardial Infarction. Journal of Clinical Medicine, 2022, 11, 1509.	1.0	6
9	Percutaneous Transvalvular Microaxial Flow Pump Support in Cardiology. Circulation, 2022, 145, 1254-1284.	1.6	29
10	Additive Impact of Interleukin 6 and Neuron Specific Enolase for Prognosis in Patients With Out-of-Hospital Cardiac Arrest â€“ Experience From the HAnnover COoling REgistry. Frontiers in Cardiovascular Medicine, 2022, 9, .	1.1	4
11	Advanced Preconditioning: Impella 5.5 Support for Decompensated Heart Failure Before Left Ventricular Assist Device Surgery. Cardiovascular Revascularization Medicine, 2021, 28, 189-192.	0.3	3
12	Anti-thrombotic strategies in patients with atrial fibrillation undergoing PCI. Clinical Research in Cardiology, 2021, 110, 759-774.	1.5	6
13	Inclusion of oral glucose tolerance testing for diabetes screening in patients with ST-elevation myocardial infarction. European Journal of Preventive Cardiology, 2021, , .	0.8	0
14	Molecular Imaging Identifies Fibroblast Activation Beyond the Infarct Region AfterÂAcute MyocardialÂInfarction. Journal of the American College of Cardiology, 2021, 77, 1835-1837.	1.2	33
15	High rate of critical coronary stenosis in comatose patients with Non-ST-elevation out-of-hospital cardiac arrest (NSTE-OHCA) undergoing therapeutic hypothermiaâ€"Experience from the HAnnover COoling REgistry (HACORE). PLoS ONE, 2021, 16, e0251178.	1.1	1
16	Complete Revascularisation in Impella-Supported Infarct-Related Cardiogenic Shock Patients Is Associated With Improved Mortality. Frontiers in Cardiovascular Medicine, 2021, 8, 678748.	1.1	11
17	Unloading in Refractory Cardiogenic Shock After Out-Of-Hospital Cardiac Arrest Due to Acute Myocardial Infarctionâ€"A Propensity Score-Matched Analysis. Frontiers in Cardiovascular Medicine, 2021, 8, 704312.	1.1	4
18	Neuromarkers and neurological outcome in out-of-hospital cardiac arrest patients treated with therapeutic hypothermiaâ€“experience from the HAnnover COoling REgistry (HACORE). PLoS ONE, 2021, 16, e0245210.	1.1	13

#	Article	IF	Citations
19	P2Y12 inhibition in acute coronary syndromes treated with percutaneous intervention â€“ Understanding the debate on Prasugrel or Ticagrelor. , 2021, , 108029.		2
20	Mortality in patients with cardiogenic shock treated with the Impella CP microaxial pump for isolated left ventricular failure. European Heart Journal: Acute Cardiovascular Care, 2020, 9, 138-148.	0.4	28
21	Cardiogenic shock complicating peripartum cardiomyopathy: Importance of early left ventricular unloading and bromocriptine therapy. European Heart Journal: Acute Cardiovascular Care, 2020, 9, 173-182.	0.4	43
22	Anti-thrombotic strategies in elderly patients receiving platelet inhibitors. European Heart Journal - Cardiovascular Pharmacotherapy, 2020, 6, 57-68.	1.4	13
23	Response to: Antithrombotic therapy for elderly patients with acute coronary syndrome: reasons to be cautious. European Heart Journal - Cardiovascular Pharmacotherapy, 2020, 6, 70-70.	1.4	0
24	Six months follow-up of protected high-risk percutaneous coronary intervention with the microaxial Impella pump: results from the German Impella registry. Coronary Artery Disease, 2020, 31, 237-242.	0.3	13
25	Diverging Trends in Age at First Myocardial Infarction: Evidence from Two German Population-Based Studies. Scientific Reports, 2020, 10, 9610.	1.6	13
26	Prevention and treatment of pulmonary congestion in patients undergoing venoarterial extracorporeal membrane oxygenation for cardiogenic shock. European Heart Journal, 2020, 41, 3753-3761.	1.0	48
27	Mechanical circulatory support in refractory cardiogenic shock due to influenza virus-related myocarditis. European Respiratory Journal, 2020, 56, 2000925.	3.1	7
28	Influence of Timing and Predicted Risk on Mortality in Impella-Treated Infarct-Related Cardiogenic Shock Patients. Frontiers in Cardiovascular Medicine, 2020, 7, 74.	1.1	27
29	Early Escalation of Mechanical Circulatory Support Stabilizes and Potentially Rescues Patients in Refractory Cardiogenic Shock. Circulation: Heart Failure, 2020, 13, e005853.	1.6	63
30	Anticoagulants for Stroke Prevention in Atrial Fibrillation in Elderly Patients. Cardiovascular Drugs and Therapy, 2020, 34, 555-568.	1.3	27
31	Standardized secondary prevention in patients with ST-elevation myocardial infarction. European Journal of Preventive Cardiology, 2020, , .	0.8	4
32	Use of extracorporeal membrane oxygenation for eCPR in the emergency room in patients with refractory out-of-hospital cardiac arrest. PLoS ONE, 2020, 15, e0239777.	1.1	12
33	Early use of hemoadsorption in patients after out-of hospital cardiac arrest â€“ a matched pair analysis. PLoS ONE, 2020, 15, e0241709.	1.1	14
34	Title is missing!. , 2020, 15, e0239777.		0
35	Title is missing!. , 2020, 15, e0239777.		0
36	Title is missing!. , 2020, 15, e0239777.		0

#	Article	IF	Citations
37	Title is missing!. , 2020, 15, e0239777.		0
38	Maintenance Immunosuppression Is Associated With Better Outcome in the 2017/2018 Influenza Epidemic. Open Forum Infectious Diseases, 2019, 6, ofz381.	0.4	2
39	Use of Impella heart pump for management of women with peripartum cardiogenic shock. Clinical Cardiology, 2019, 42, 974-981.	0.7	31
40	Rationale and design of DanGer shock: Danish-German cardiogenic shock trial. American Heart Journal, 2019, 214, 60-68.	1.2	160
41	Clinical scenarios for use of transvalvular microaxial pumps in acute heart failure and cardiogenic shock â€“ A European experienced users working group opinion. International Journal of Cardiology, 2019, 291, 96-104.	0.8	30
42	Prediction of heart failure and death in an adult population of Fontan patients. Cardiology in the Young, 2019, 29, 602-609.	0.4	7
43	Haemodynamic simulation and the effect of early left ventricular unloading in preâ€shock acute coronary syndrome. ESC Heart Failure, 2019, 6, 457-463.	1.4	16
44	Safe Exchange of a Transfemoral Impella Pump. Cardiovascular Revascularization Medicine, 2019, 20, 827-828.	0.3	2
45	Impella Support for Acute Myocardial Infarction Complicated by Cardiogenic Shock. Circulation, 2019, 139, 1249-1258.	1.6	353
46	The short- and long-term risks of venoarterial extracorporeal membrane oxygenation watershed. European Journal of Cardio-thoracic Surgery, 2018, 53, 894-894.	0.6	4
47	Indication and short-term clinical outcomes of high-risk percutaneous coronary intervention with microaxial ImpellaÂ® pump: results from the German ImpellaÂ® registry. Clinical Research in Cardiology, 2018, 107, 653-657.	1.5	30
48	The cVAD registry for percutaneous temporary hemodynamic support: A prospective registry of Impella mechanical circulatory support use in high-risk PCI, cardiogenic shock, and decompensated heart failure. American Heart Journal, 2018, 199, 115-121.	1.2	61
49	The No-Win Resuscitation: Ventricular Septal Rupture and Associated Acute Aortic Occlusion. Case Reports in Critical Care, 2018, 2018, 1-4.	0.2	0
50	Mortality in Patients With Out-of-Hospital Cardiac Arrest Undergoing a Standardized Protocol Including Therapeutic Hypothermia and RoutineÂCoronary Angiography. JACC: Cardiovascular Interventions, 2018, 11, 1811-1820.	1.1	35
51	Thrombus Aspiration for ST-Segmentâ€“Elevation Myocardial Infarction in Modern Era. Circulation: Cardiovascular Interventions, 2017, 10, .	1.4	23
52	Venoarterial Extracorporeal Membrane Oxygenation: Lower Speed, and You May BeÂFaster. Annals of Thoracic Surgery, 2017, 104, 724-725.	0.7	4
53	First-in-Man Fully Percutaneous Complete Bypass of Heart and Lung. JACC: Cardiovascular Interventions, 2017, 10, e231-e233.	1.1	20
54	The novel mineralocorticoid receptor antagonist finerenone attenuates neointima formation after vascular injury. PLoS ONE, 2017, 12, e0184888.	1.1	34

#	Article	IF	Citations
55	Efficacy of prasugrel administration immediately after percutaneous coronary intervention in ST-elevation myocardial infarction. Thrombosis and Haemostasis, 2017, 117, 99-104.	1.8	14
56	Acquired von Willebrand syndrome in cardiogenic shock patients on mechanical circulatory microaxial pump support. PLoS ONE, 2017, 12, e0183193.	1.1	33
57	Giant pericardial effusion: drain it all?. European Heart Journal, 2016, 37, 2383-2383.	1.0	0
58	Platelet inhibition with prasugrel in patients with acute myocardial infarction undergoing therapeutic hypothermia after cardiopulmonary resuscitation. Thrombosis and Haemostasis, 2016, 115, 960-968.	1.8	11
59	Cannulation strategies for percutaneous extracorporeal membrane oxygenation in adults. Clinical Research in Cardiology, 2016, 105, 283-296.	1.5	197
60	The Nitric Oxide Donor Pentaerythritol Tetranitrate Reduces Platelet Activation in Congestive Heart Failure. PLoS ONE, 2015, 10, e0123621.	1.1	13
61	Molecular Imaging of the Chemokine Receptor CXCR4 After Acute Myocardial Infarction. JACC: Cardiovascular Imaging, 2015, 8, 1417-1426.	2.3	159
62	Phosphorothioate backbone modifications of nucleotide-based drugs are potent platelet activators. Journal of Experimental Medicine, 2015, 212, 129-137.	4.2	87
63	Heart against veno-arterial ECMO: Competition visualized. International Journal of Cardiology, 2015, 187, 164-165.	0.8	36
64	Modulation of platelet and monocyte function by the chemokine fractalkine (<scp>CX</scp>₃<scp>CL</scp>1) in cardiovascular disease. European Journal of Clinical Investigation, 2015, 45, 624-633.	1.7	37
65	Impella ventricular support in clinical practice: Collaborative viewpoint from a European expert user group. International Journal of Cardiology, 2015, 201, 684-691.	0.8	160
66	Characterizing the Inflammatory Tissue Response to Acute Myocardial Infarction by Clinical Multimodality Noninvasive Imaging. Circulation: Cardiovascular Imaging, 2014, 7, 811-818.	1.3	82
67	Fractalkine promotes platelet activation and vascular dysfunction in congestive heart failure. Thrombosis and Haemostasis, 2014, 111, 725-735.	1.8	16
68	The direct factor Xa inhibitor Rivaroxaban reduces platelet activation in congestive heart failure. Pharmacological Research, 2013, 74, 49-55.	3.1	21
69	Fractalkine Activates a Signal Transduction Pathway Similar to P2Y ₁₂ and Is Associated With Impaired Clopidogrel Responsiveness. Arteriosclerosis, Thrombosis, and Vascular Biology, 2012, 32, 1832-1840.	1.1	12
70	Breaking Resistance: Is There Still a Reason for Clopidogrel in Acute STEMI?. Cardiovascular Drugs and Therapy, 2012, 26, 365-366.	1.3	0
71	Fractalkine Is Expressed in Early and Advanced Atherosclerotic Lesions and Supports Monocyte Recruitment via CX3CR1. PLoS ONE, 2012, 7, e43572.	1.1	51
72	Fractalkine â€“ a local inflammatory marker aggravating platelet activation at the vulnerable plaque. Thrombosis and Haemostasis, 2012, 108, 457-463.	1.8	26

#	Article	IF	Citations
73	Early determination of clopidogrel responsiveness by platelet reactivity index identifies patients at risk for cardiovascular events after myocardial infarction. Thrombosis and Haemostasis, 2011, 106, 141-148.	1.8	15
74	Clopidogrel improves endothelial function and NO bioavailability by sensitizing adenylyl cyclase in rats with congestive heart failure. Basic Research in Cardiology, 2011, 106, 485-494.	2.5	20
75	The H2-receptor antagonist ranitidine interferes with clopidogrel-mediated P2Y12 inhibition in platelets. Pharmacological Research, 2010, 62, 352-356.	3.1	8
76	Guanylyl cyclase activator ataciguat improves vascular function and reduces platelet activation in heart failure. Pharmacological Research, 2010, 62, 432-438.	3.1	31
77	Inhibition of platelet activation in rats with severe congestive heart failure by a novel endothelial nitric oxide synthase transcription enhancer. European Journal of Heart Failure, 2009, 11, 336-341.	2.9	18
78	ADP-induced platelet aggregation frequently fails to detect impaired clopidogrel-responsiveness in patients with coronary artery disease compared to a P2Y12-specific assay. Thrombosis and Haemostasis, 2008, 100, 618-625.	1.8	28
79	ADP-induced platelet aggregation frequently fails to detect impaired clopidogrel-responsiveness in patients with coronary artery disease compared to a P2Y12-specific assay. Thrombosis and Haemostasis, 2008, 100, 618-25.	1.8	5
80	Chemokine Fractalkine Mediates Leukocyte Recruitment to Inflammatory Endothelial Cells in Flowing Whole Blood. Circulation, 2007, 116, 764-773.	1.6	145
81	The CX3C Chemokine Fractalkine Induces Vascular Dysfunction by Generation of Superoxide Anions. Arteriosclerosis, Thrombosis, and Vascular Biology, 2007, 27, 55-62.	1.1	34
82	Rosuvastatin Reduces Platelet Activation in Heart Failure. Arteriosclerosis, Thrombosis, and Vascular Biology, 2005, 25, 1071-1077.	1.1	64
83	Reduced Vascular NO Bioavailability in Diabetes Increases Platelet Activation In Vivo. Arteriosclerosis, Thrombosis, and Vascular Biology, 2004, 24, 1720-1726.	1.1	54
84	Rapid Regulation of Platelet Activation In Vivo by Nitric Oxide. Circulation, 2004, 109, 1819-1822.	1.6	132
85	Novel role of the membrane-bound chemokine fractalkine in platelet activation and adhesion. Blood, 2004, 103, 407-412.	0.6	124
86	Endothelial Dysfunction in Heart Failure: Mechanisms and Therapeutic Approaches. Current Vascular Pharmacology, 2004, 2, 115-124.	0.8	63
87	Addition of the selective aldosterone receptor antagonist eplerenone to ACE inhibition in heart failure: effect on endothelial dysfunction. Cardiovascular Research, 2003, 58, 655-662.	1.8	58
88	Inhibition of platelet activation in congestive heart failure by aldosterone receptor antagonism and ACE inhibition. Thrombosis and Haemostasis, 2003, 89, 1024-1030.	1.8	57
89	Inhibition of platelet activation in congestive heart failure by aldosterone receptor antagonism and ACE inhibition. Thrombosis and Haemostasis, 2003, 89, 1024-30.	1.8	13